Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01350141 · ClinicalTrials.gov registry record · Phase 2
A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT01350141: Completed Phase 2 study, sponsored by Pfizer.
NCT01350141 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 46 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01350141, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
PF-04950615 is a new investigational hypercholesterolemic agent that is being tested in this study to evaluate if it can lower LDL cholesterol.
Primary Outcome
Baseline value was calculated as the average of Day 7 and Day 1 measurements collected prior to study drug administration.
Interventions
- OTHER Placebo
- DRUG PF-04950615 (RN316)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
What the finished NCT01350141 record still lists
NCT01350141 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01350141 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01350141 about?
NCT01350141 is a clinical study titled "A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins". PF-04950615 is a new investigational hypercholesterolemic agent that is being tested in this study to evaluate if it can lower LDL cholesterol.
What is the current status of trial NCT01350141?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2011-06. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01350141?
The interventions under investigation include: Placebo (OTHER), PF-04950615 (RN316) (DRUG).
Who is sponsoring clinical trial NCT01350141?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01350141's enrollment target sits among peer trials
46 1286th of 2000 higher than 705 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia